--- title: "Century Therapeutics, Inc. (NASDAQ:IPSC) Receives Consensus Recommendation of \"Hold\" from Analysts" type: "News" locale: "en" url: "https://longbridge.com/en/news/296803915.md" description: "Century Therapeutics (NASDAQ:IPSC) has a consensus 'Hold' rating from seven analysts, with four buys, two holds, and one sell. The average 12-month price target is $4.75. Recent analyst actions include Weiss Ratings reaffirming a 'sell' rating and Mizuho initiating coverage with an 'outperform' rating and $8.00 target. Institutional investors like Bank of America and AQR Capital increased their stakes significantly in recent quarters. The stock traded at $2.12, with Q2 EPS missing estimates at -$0.17." datetime: "2026-08-24T14:44:22.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/296803915.md) - [en](https://longbridge.com/en/news/296803915.md) - [zh-HK](https://longbridge.com/zh-HK/news/296803915.md) generator: "portal-rs" --- # Century Therapeutics, Inc. (NASDAQ:IPSC) Receives Consensus Recommendation of "Hold" from Analysts Shares of Century Therapeutics, Inc. (NASDAQ:IPSC - Get Free Report) have earned a consensus recommendation of "Hold" from the seven ratings firms that are presently covering the firm, Marketbeat.com reports. One investment analyst has rated the stock with a sell recommendation, two have assigned a hold recommendation and four have given a buy recommendation to the company. The average 12 month target price among analysts that have issued ratings on the stock in the last year is $4.75. Get **Century Therapeutics** alerts: A number of analysts recently weighed in on the stock. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Century Therapeutics in a research note on Thursday, July 2nd. Mizuho initiated coverage on shares of Century Therapeutics in a research report on Wednesday, May 27th. They issued an "outperform" rating and a $8.00 price target for the company. Finally, Wall Street Zen lowered shares of Century Therapeutics from a "hold" rating to a "sell" rating in a report on Saturday, June 27th. **Check Out Our Latest Analysis on Century Therapeutics** ## Institutional Inflows and Outflows Institutional investors and hedge funds have recently made changes to their positions in the stock. Bank of America Corp DE lifted its stake in shares of Century Therapeutics by 109.1% during the 4th quarter. Bank of America Corp DE now owns 66,043 shares of the company's stock worth $67,000 after purchasing an additional 34,466 shares during the last quarter. AQR Capital Management LLC raised its holdings in Century Therapeutics by 358.9% in the first quarter. AQR Capital Management LLC now owns 111,079 shares of the company's stock worth $53,000 after purchasing an additional 86,875 shares in the last quarter. Goldman Sachs Group Inc. lifted its position in shares of Century Therapeutics by 26.9% during the first quarter. Goldman Sachs Group Inc. now owns 179,635 shares of the company's stock valued at $86,000 after buying an additional 38,052 shares during the last quarter. Acadian Asset Management LLC boosted its holdings in shares of Century Therapeutics by 101.2% in the 1st quarter. Acadian Asset Management LLC now owns 284,229 shares of the company's stock valued at $133,000 after buying an additional 142,953 shares in the last quarter. Finally, Prudential Financial Inc. purchased a new position in shares of Century Therapeutics in the 2nd quarter worth approximately $25,000. 50.20% of the stock is currently owned by hedge funds and other institutional investors. ## Century Therapeutics Stock Performance Century Therapeutics stock traded up $0.04 during trading hours on Monday, hitting $2.12. The company had a trading volume of 119,647 shares, compared to its average volume of 1,389,911. The firm has a market cap of $382.96 million, a P/E ratio of -2.27 and a beta of 1.57. Century Therapeutics has a 1 year low of $0.44 and a 1 year high of $3.04. The company has a 50-day moving average price of $2.18 and a two-hundred day moving average price of $2.21. Century Therapeutics (NASDAQ:IPSC - Get Free Report) last issued its earnings results on Wednesday, August 12th. The company reported ($0.17) EPS for the quarter, missing analysts' consensus estimates of ($0.11) by ($0.06). As a group, equities research analysts anticipate that Century Therapeutics will post -0.47 EPS for the current year. ## Century Therapeutics Company Profile (Get Free Report) Century Therapeutics is a clinical-stage biotechnology company focused on the discovery and development of allogeneic cell therapies for cancer. Utilizing induced pluripotent stem cell (iPSC) technology, the company engineers “off-the-shelf” natural killer (NK) and T cell candidates designed to target hematologic malignancies and solid tumors. By harnessing iPSC-derived immune cells, Century aims to overcome challenges associated with patient-derived therapies, such as manufacturing variability and treatment delays. The company's proprietary platform integrates gene editing, synthetic biology and scalable cell expansion processes to generate a pipeline of product candidates. ## Further Reading - Five stocks we like better than Century Therapeutics - Marvell Takes a Shot a Broadcom's Throne With Google Deal - 5 of the Most-Upgraded Stocks Over the Last Quarter Are All Software Names—Here's Why - Aehr Test Systems Soars Again on Latest Orders, Jefferies Eyes Big-Time Upside Ahead - Walmart and Home Depot Earnings Show the K (Shaped Economy) Is Here to Stay *This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.* Continue following MarketBeat Add MarketBeat as your preferred source on Google to see our latest stories in your feed. Add As Preferred Source ## Should You Invest $1,000 in Century Therapeutics Right Now? Before you consider Century Therapeutics, you'll want to hear this. MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Century Therapeutics wasn't on the list. While Century Therapeutics currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys. View The Five Stocks Here ### Related Stocks - [IPSC.US](https://longbridge.com/en/quote/IPSC.US.md) - [BAC.US](https://longbridge.com/en/quote/BAC.US.md) - [MFG.US](https://longbridge.com/en/quote/MFG.US.md) - [8411.JP](https://longbridge.com/en/quote/8411.JP.md) - [GS.US](https://longbridge.com/en/quote/GS.US.md) - [PRU.US](https://longbridge.com/en/quote/PRU.US.md) - [MRVL.US](https://longbridge.com/en/quote/MRVL.US.md) - [AVGO.US](https://longbridge.com/en/quote/AVGO.US.md) - [GOOGL.US](https://longbridge.com/en/quote/GOOGL.US.md) - [GOOG.US](https://longbridge.com/en/quote/GOOG.US.md) - [AEHR.US](https://longbridge.com/en/quote/AEHR.US.md) - [JEF.US](https://longbridge.com/en/quote/JEF.US.md) - [WMT.US](https://longbridge.com/en/quote/WMT.US.md) - [HD.US](https://longbridge.com/en/quote/HD.US.md) - [BAC-Q.US](https://longbridge.com/en/quote/BAC-Q.US.md) - [BML-L.US](https://longbridge.com/en/quote/BML-L.US.md) - [BAC-L.US](https://longbridge.com/en/quote/BAC-L.US.md) - [BAC-K.US](https://longbridge.com/en/quote/BAC-K.US.md) - [BML-H.US](https://longbridge.com/en/quote/BML-H.US.md) - [BAC-N.US](https://longbridge.com/en/quote/BAC-N.US.md) - [BAC-E.US](https://longbridge.com/en/quote/BAC-E.US.md) - [MER-K.US](https://longbridge.com/en/quote/MER-K.US.md) - [BAC-O.US](https://longbridge.com/en/quote/BAC-O.US.md) - [BML-G.US](https://longbridge.com/en/quote/BML-G.US.md) - [BAC-M.US](https://longbridge.com/en/quote/BAC-M.US.md) - [BAC-B.US](https://longbridge.com/en/quote/BAC-B.US.md) - [BML-J.US](https://longbridge.com/en/quote/BML-J.US.md) - [BAC-S.US](https://longbridge.com/en/quote/BAC-S.US.md) - [BAC-P.US](https://longbridge.com/en/quote/BAC-P.US.md) - [8648.JP](https://longbridge.com/en/quote/8648.JP.md) - [W4VR.SG](https://longbridge.com/en/quote/W4VR.SG.md) - [PRS.US](https://longbridge.com/en/quote/PRS.US.md) - [PFH.US](https://longbridge.com/en/quote/PFH.US.md) - [PRH.US](https://longbridge.com/en/quote/PRH.US.md) ## Related News & Research - [Meeder Advisory Services Inc. Invests $8.19 Million in Bank of America Corporation $BAC](https://longbridge.com/en/news/296678230.md) - [Argyle Capital Partners LLC Purchases Shares of 9,375 Bank of America Corporation $BAC](https://longbridge.com/en/news/296675010.md) - [Itron, Inc. (NASDAQ:ITRI) Receives Consensus Rating of "Moderate Buy" from Analysts](https://longbridge.com/en/news/296185249.md) - [Bank of America tops 10% stake in Lakefront Biotherapeutics voting rights disclosure](https://longbridge.com/en/news/296823581.md) - [Kesler Norman & Wride LLC Makes New Investment in Bank of America Corporation $BAC](https://longbridge.com/en/news/296080944.md) --- > **Disclaimer: This article is for reference only and does not constitute any investment advice.**